Aspirin Dosing Before Cardiac Catheterization
For patients already on daily aspirin, continue 81–325 mg before PCI; for aspirin-naïve patients, give 325 mg of non-enteric-coated aspirin as soon as possible before the procedure. 1, 2, 3, 1
Dosing Algorithm
If Patient Already Taking Daily Aspirin:
- Continue current dose (81–325 mg) before catheterization 1, 2
- No need to increase from 81 mg to 325 mg if already on low-dose therapy
- Use non-enteric-coated formulation for faster absorption
If Patient NOT on Aspirin (Aspirin-Naïve):
- Give 325 mg non-enteric-coated aspirin as soon as possible before PCI 2, 3
- For STEMI patients specifically: 162–325 mg loading dose 3
- Administer at least 2 hours before procedure, preferably 24 hours when possible 4
Post-Procedure Maintenance
After catheterization, 81 mg daily is the preferred maintenance dose rather than higher doses 1. This recommendation is based on:
- Equivalent cardiovascular protection with lower bleeding risk 5
- Class IIa recommendation (reasonable preference) for 81 mg maintenance 1
- Research showing no difference in major adverse cardiovascular events between 81 mg and 325 mg, but increased minor bleeding with higher doses 6
Key Clinical Considerations
The critical distinction is pre-procedure loading versus maintenance dosing. The guidelines consistently recommend:
- Loading phase: Higher dose (325 mg) for aspirin-naïve patients ensures rapid platelet inhibition
- Maintenance phase: Lower dose (81 mg) provides equivalent protection with better safety profile
Common pitfall to avoid: Do not routinely increase aspirin from 81 mg to 325 mg in patients already on daily low-dose therapy. The 2011 and 2014 ACC/AHA guidelines explicitly state that patients already taking daily aspirin should continue their current dose (81–325 mg range) 1, 2.
Practical implementation: If a patient presents on 81 mg daily aspirin for chronic therapy, simply ensure they took their usual dose—no need to give additional aspirin. If they're aspirin-naïve, load with 325 mg non-enteric-coated formulation.
The evidence from ADAPTABLE trial 5 and TRANSLATE-ACS 6 confirms no cardiovascular benefit to higher maintenance doses, while demonstrating increased bleeding complications, supporting the guideline preference for 81 mg maintenance dosing post-procedure.